(Q36467502)

English

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

based on heuristic

inferred from title

author name string

Crighton IL

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dowsett M

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Lal A

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Man A

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Smith IE

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

1 October 1989

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

60

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

644-648

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Prognostic significance of serum prolactin levels in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247121

30 September 2017

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247121

30 September 2017

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247121

30 September 2017

Source of Estrogen Production in Postmenopausal Women1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247121

28 June 2018

Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247121

28 June 2018

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aminoglutethimide dose and hormone suppression in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists*

1 reference

https://pubmed.ncbi.nlm.nih.gov/2508735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1989.331

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36467502&oldid=2198935875"